×
About 20,410 results

ALLMedicine™ Hypercholesterolemia Center

Research & Reviews  5,157 results

Association of Dementia Risk With Focal Epilepsy and Modifiable Cardiovascular Risk Fac...
https://doi.org/10.1001/jamaneurol.2023.0339
JAMA Neurology; Tai XY, Torzillo E et. al.

Mar 28th, 2023 - Epilepsy has been associated with cognitive impairment and potentially dementia in older individuals. However, the extent to which epilepsy may increase dementia risk, how this compares with other neurological conditions, and how modifiable cardio...

Concurrent Living Donor Liver Transplantation and Off-Pump Coronary Artery Bypass in a ...
https://doi.org/10.1016/j.transproceed.2023.02.024
Transplantation Proceedings; Kazimi M, Mahmudov R et. al.

Mar 27th, 2023 - Homozygous familial hypercholesterolemia (FH) is a rare disease that causes serious cardiovascular problems and may be fatal even at an early age. Because this disease variant is rather aggressive, the effect of lipid-lowering agents and lipid aph...

Parental Attitudes and Ideas Regarding Newborn Screening for Familial Hypercholesterole...
https://doi.org/10.1007/s10995-023-03640-5
Maternal and Child Health Journal; Tobik K, Orland KM et. al.

Mar 26th, 2023 - Familial hypercholesterolemia (FH) is an inherited disease which causes premature atherosclerotic cardiovascular disease. However, less than 10% of individuals with FH have been identified. To assess parental perspectives for inclusion of FH on ro...

The renal artery-aorta angle associated with renal artery plaque: a retrospective analy...
https://doi.org/10.1186/s12880-023-00997-5
BMC Medical Imaging; Yang H, Yang R

Mar 26th, 2023 - To investigate the relationship between renal artery anatomical configuration and renal artery plaque (RAP) based on 320-row CT. The abdominal contrast-enhanced CT data from 210 patients was retrospectively analyzed. Among 210 patients, there were...

Using random-forest multiple imputation to address bias of self-reported anthropometric...
https://doi.org/10.1186/s12874-023-01892-x
BMC Medical Research Methodology; Pelgrims I, Devleesschauwer B et. al.

Mar 26th, 2023 - In many countries, the prevalence of non-communicable diseases risk factors is commonly assessed through self-reported information from health interview surveys. It has been shown, however, that self-reported instead of objective data lead to an u...

see more →

Guidelines  9 results

The Detection, Evaluation, and Management of Dyslipidemia in Children and Adolescents: ...
https://doi.org/10.1016/j.cjca.2022.05.002
The Canadian Journal of Cardiology; Khoury M, Bigras JL et. al.

Aug 13th, 2022 - Atherosclerosis begins in youth and is directly linked with the presence and severity of cardiovascular risk factors, including dyslipidemia. Thus, the timely identification and management of dyslipidemia in childhood might slow atherosclerotic pr...

The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines fo...
https://doi.org/10.1530/EJE-21-0479
European Journal of Endocrinology; Bartalena L, Kahaly GJ et. al.

Jul 24th, 2021 - Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease (GD). Choice of treatment should be based on the assessment of clinical activity and severity of GO. Early referral to specialized centers is fundamental for most...

Evaluation and Management of Dyslipidemia in Patients Treated with Lorlatinib.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985771
Current Oncology (Toronto, Ont.); Blais N, Adam JP et. al.

Jan 4th, 2021 - The use of lorlatinib, an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of ALK-positive metastatic non-small cell lung cancer, is associated with dyslipidemia in over 80% of patients. Clinical trial protocols for the management of l...

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Up...
https://doi.org/10.1016/j.cjca.2018.09.005
The Canadian Journal of Cardiology; Brunham LR, Ruel I et. al.

Dec 12th, 2018 - Familial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide, and of the approximately 145,000 Canadians estimated to have FH, most are...

Joint position statement on "Nutraceuticals for the treatment of hypercholesterolemia" ...
https://doi.org/10.1016/j.numecd.2016.11.122
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Pirro M, Vetrani C et. al.

Dec 14th, 2016 - Evidence showed that LDL-cholesterol lowering is associated with a significant cardiovascular risk reduction. The initial therapeutic approach to hypercholesterolemia includes dietary modifications but the compliance to recommendations is often in...

see more →

Drugs  1,203 results see all →

Clinicaltrials.gov  747 results

Equitable Implementation of Cascade Screening for Familial Hypercholesterolemia
https://clinicaltrials.gov/ct2/show/NCT05430191

Mar 23rd, 2023 - Aim 1. Conduct interviews with patients with high cholesterol and/or FH and clinicians to identify common barriers and facilitators for individuals to engage in cascade screening. These activities will occur in the first 7 months and will serve as...

The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
https://clinicaltrials.gov/ct2/show/NCT01109368

Mar 17th, 2023 - Detailed information of "standard of care" procedures will be compiled in a database. These include medical history and physical exam, lipid profiles and other standard blood tests, dietary evaluation and counseling, cardiology evaluation includin...

Peripheral Treg Cell Senescence & Serum Total Cholesterol Level
https://clinicaltrials.gov/ct2/show/NCT05680844

Mar 10th, 2023 - Hypercholesterolemia is a risk factor for the occurrence and development of atherosclerosis. Recent animal studies have found that increased serum cholesterol level is associated with peripheral Treg cell senescence, but clinical evidence is still...

A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501
https://clinicaltrials.gov/ct2/show/NCT04080050

Mar 9th, 2023 - Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic metabolic disorder characterized by absent or severely reduced capacity to catabolize circulating LDL particles by the hepatic LDL receptor. As a consequence, HoFH subjects present ...

A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Compared With Placebo in Adult Participants
https://clinicaltrials.gov/ct2/show/NCT05762276

Mar 9th, 2023 - This is multisite, randomized, double-blind, placebo-controlled, multidose regimen, phase 1, first-in-human study of VXX-401, a synthetic peptide-based active immunotherapy candidate for preventing and treating hypercholesterolemia. The study will...

see more →

News  1,033 results

Cholera Outbreak Widens; What Beethoven's DNA Revealed; Grindr's Free HIV Tests
https://www.medpagetoday.com/infectiousdisease/generalinfectiousdisease/103673

Mar 23rd, 2023 - Note that some links may require subscriptions. Four new countries are reporting cholera outbreaks, bringing the total number of affected countries to 24, according to the World Health Organization. Come May, the White House COVID-19 task force wi...

Cardiometabolic Changes in Early Life Favor Girls
https://www.medpagetoday.com/cardiology/prevention/103551

Mar 15th, 2023 - Sex differences in adult heart disease may be related to diverging trajectories in cardiometabolic disease factors beginning as early as childhood, a metabolomics study showed. With granular and high-resolution cardiovascular phenotyping, the diff...

Insomnia and MIs; LGBTQ Heart Health; Trifecta SAVR Valves Not So Durable
https://www.medpagetoday.com/cardiology/prevention/103309

Feb 28th, 2023 - Meta-analysis makes the case for insomnia as a risk factor for myocardial infarction. (Clinical Cardiology) Outpatient procedures associated with postoperative heart attacks included gastrointestinal endoscopy, as well as vascular, urological/gyne...

Facial lipoatrophy with semaglutide-related weight loss
https://www.mdedge.com/dermatology/article/261159/aesthetic-dermatology/facial-lipoatrophy-semaglutide-related-weight-loss
Naissan O. Wesley, MD

Feb 10th, 2023 - Ozempic and Wegovy are two prescription drugs that have transformed the management of type 2 diabetes and obesity. Both are a form of semaglutide; the Food and Drug Administration approved Ozempic for treating type 2 diabetes in 2017, followed by.

Muscle-Related Adverse Events Associated With PCSK9 Inhibitors in a Veteran Population
https://www.mdedge.com/fedprac/article/261134/mixed-topics/muscle-related-adverse-events-associated-pcsk9-inhibitors
Joseph Cencetti, PharmD, BCACP, CLS, Callie Abramowitz, PharmD et. al.

Feb 9th, 2023 - HMG-CoA reductase inhibitors (statins) have been shown to effectively reduce low-density lipoprotein cholesterol (LDL-C) as well as morbidity and mortality in patients who have either atherosclerotic cardiovascular disease (ASCVD) or risk factors.

see more →

Patient Education  15 results see all →